Bionor Pharma new strategy aims at ‘Functional Cure for HIV’
Authored by Karl Simpson
Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Algeta, Anker Lundemose, Bionor Pharma, Board of Directors, celgene, CEO, CFO, Ferring International, HDAC inhibitor, HIV, Jerry Zeldis, Kick, Kick Kill Boost, Lenalidomide, Marianne Kock, Oystein Soung, Pronova Biopharma, Synne Roine, Vacc-4x, Vice General Manager
Leave a comment
FDA and EMA to collaborate on orphan drugs and meet industry
Authored by Karl Simpson
Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged EMA, European Medicines Agency, EURORDIS, FDA, FDA Orphan Products Grant program, Humanitarian Use Device, multi-stakeholder, Orphan drugs, Orphan Product Designation, regulatory, regulatory affairs, The Food and Drug Administration
Leave a comment
Liftstream Life Science Newsletter August Edition
The August edition of the newsletter contains
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business, Recruitment Market
Tagged Audentes Therapeutics, august, big pharma, biotechnology, bioValley, CEO, Cluster, Duchenne Muscular Dystrophy, Inflection bioscience, Ipsen, Karl Simpson, Liftstream, Liftstream Newsletter, managing conflict, Michael O'Neill, pharmaceutical, start up, Syntaxin, venture capital, venturing financing
1 Comment
NPS Pharma enrols first patient in global registry for Hypoparathyroidism
Authored by James Sheppard
Massachusetts biotech continues to excite with new investments
Authored by Karl Simpson
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Abingworth Management, BioPharma America, Biotechnology cluster, Boston, Brookside Capital, Cristina Csimma, Cydan, David Mott, Deerfield, DELPHI, Dicer Substrate siRNA, Dicerna Pharmaceuticals, drug delivery technologies, Duchenne Muscular Dystrophy, EDI200, Edimer Pharmaceuticals, EnCore™, exon skipping, Exportin-1, Forsite Capital Management, Genzyme, Inhibitors of Nuclear Export, innovation, investors, Karyopharm Therapeutics, Massachusetts, Neil Kirby, New Enterprise Associates, New Leaf Venture Partners, NEZ, Omega Funds, oncology market, Orphan Drug, Prosensa, RA Capital, Rare Disease, Sanofi, Series B, SR One, Third Rock Ventures, TKT, undruggable disease, Vertex Pharmaceuticals, X-linked Hypohidrotic Ectodermal Dysplasia, XLHED
Leave a comment
BrainStorms’s Cell Therapy receives Orphan Drug Designation in EU
Authored by James Sheppard
Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged ALS, Amyotrophic Lateral Sclerosis, BrainStorm, Brainstorm Cell Therapeutics, Cell Therapy, clinical studies, Dana-Fabre Cancer Institute, EMA, European Medicine Agency, FDA, Israel, multi-centre phase IIa trial, NurOwn, orphan drug designation, phase IIa clinical trials, Stem Cell Therapy
Leave a comment
